Francesco Dati
Research Subjects
Francesco Dati has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
Carola Wagner
Behring Diagnostics GmbH, Scientific Affairs, P.O. Box 1149, D-35001 Marburg/Germany
1 shared publication- Dirk Peetz
Klinikum der Johannes-Gutenberg-Universität Mainz
1 shared publication Frank Niemann
Behring Diagnostics GmbH, Scientific Affairs, P.O. Box 1149, D-35001 Marburg/Germany
1 shared publicationG. Hafner
Zentrum für Labormedizin und Mikrobiologie, Essen
1 shared publicationGerd Hafner
Institute for Clinical Chemistry and Laboratory Medicine, Johannes-Gutenberg-University, Langenbeckstrasse 1, D-55131 Mainz/Germany
1 shared publicationHilde Erbes
Institute for Clinical Chemistry and Laboratory Medicine, Johannes-Gutenberg-University, Langenbeckstrasse 1, D-55131 Mainz/Germany
1 shared publication
Latest Publications
- 1 July 2003
- Published by Wiley in Journal of Laboratory Medicine
- Vol. 27 (7-8) , 279-287
Patientennahe Bestimmung der Troponine zur Diagnostik akuter Koronarsyndrome. Near-patient Testing of Troponins for the Diagnosis of Acute Coronary Syndromes
- 1 July 2003
- Published by Wiley in Journal of Laboratory Medicine
- Vol. 27 (7-8) , 279-287
Patientennahe Bestimmung der Troponine zur Diagnostik akuter Koronarsyndrome. Near-patient Testing of Troponins for the Diagnosis of Acute Coronary Syndromes
- Open Access
- 1 September 1997
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 43 (9) , 1719-1723
ProC® Global: the first functional screening assay for the complete protein C pathway
In clinical practice, venous thromboembolic complications are much more frequent than bleeding disorders. In fact, disturbances within the protein C pathway due to coagulation factor V (FV) Leiden mutation and deficiency of protein C or protein S are the most frequent abnormalities in hereditary thrombophilia. Furthermore, acquired dysfunctions of the protein C system may predispose the single individual to an increased thrombotic risk. A routine-suited screening assay that would allow the monitoring of the proper interplay of factors in the protein C pathway could add an important factor to the basic coagulation profile. This consists of the prothrombin time and of the activated partial thromboplastin time, which currently allow only a screening for increased risk for bleeding but not for venous thromboembolism. A new functional screening test for the protein C system such as the presented ProC® Global should therefore facilitate detection of FV Leiden as well as deficiency of protein C and protein S. The results of the present evaluation indicate that ProC Global is highly sensitive to activated protein C resistance/FV Leiden (100%) and protein C deficiency (90%) and sensitive to protein S deficiency (63%). Furthermore, the assay gives a quantitative measure of the net potential of the protein C pathway in relation to the intrinsic procoagulant system. The use of this assay for a prospective assessment of thromboembolic risk is the subject of current studies.
- 1 September 1997
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 43 (9) , 1719-1723
Open AccessProC® Global: the first functional screening assay for the complete protein C pathway
In clinical practice, venous thromboembolic complications are much more frequent than bleeding disorders. In fact, disturbances within the protein C pathway due to coagulation factor V (FV) Leiden mutation and deficiency of protein C or protein S are the most frequent abnormalities in hereditary thrombophilia. Furthermore, acquired dysfunctions of the protein C system may predispose the single individual to an increased thrombotic risk. A routine-suited screening assay that would allow the monitoring of the proper interplay of factors in the protein C pathway could add an important factor to the basic coagulation profile. This consists of the prothrombin time and of the activated partial thromboplastin time, which currently allow only a screening for increased risk for bleeding but not for venous thromboembolism. A new functional screening test for the protein C system such as the presented ProC® Global should therefore facilitate detection of FV Leiden as well as deficiency of protein C and protein S. The results of the present evaluation indicate that ProC Global is highly sensitive to activated protein C resistance/FV Leiden (100%) and protein C deficiency (90%) and sensitive to protein S deficiency (63%). Furthermore, the assay gives a quantitative measure of the net potential of the protein C pathway in relation to the intrinsic procoagulant system. The use of this assay for a prospective assessment of thromboembolic risk is the subject of current studies.